Open-Label, Dose Increase and Phase I Study of ALT-P7 to Determine Safety, Tolerability, Pharmacokinetics for HER2 Positive Metastatic Breast Cancer Patients Who Have Progressed on Previous Trastuzumab-Based Therapy
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2018
Price : $35 *
At a glance
- Drugs ALT-P7 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Alteogen
- 08 Jul 2018 Planned End Date changed from 31 Dec 2017 to 31 Mar 2019.
- 08 Jul 2018 Planned primary completion date changed from 30 Nov 2017 to 31 Dec 2018.
- 08 Jul 2018 Status changed from not yet recruiting to recruiting.